Clinical study of myeloid-derived suppressor cell precursor differentiation in acute kidney injury based on single cell sequencing

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035944

Enrollment

Unknown

Registered

2020-08-20

Start date

2022-09-30

Completion date

Unknown

Last updated

2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Disease

Interventions

healthy control:none

kidney transplant AKI:none

AKI(without kidney transplant):none

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: One of the following three stages is sufficient: 1. The first stage: 1.5-1.9 times the upper limit of the reference value of serum creatinine or greater than or equal to 0.3mg/dl (26.5 µmol/L) increase; 2. The second stage: 2.0-2.9 times the upper limit of the reference value of serum creatinine; 3. The third stage: 3.0 times the upper limit of the reference value of serum creatinine or greater than or equal to 4.0 mg/dl (>=353.6 umol/L) increase.

Exclusion criteria

Exclusion criteria: 1. Combined with other immune diseases (such as systemic lupus erythematosus, etc.); 2. Combined pregnancy.

Design outcomes

Primary

Measure	Time frame
Peripheral blood lymphocytes;	—

Countries

China

Contacts

Public ContactYi Zhang

Fudan University Zhongshan Hospital

yzhang_sjtu@126.com+86 15901844829

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026